Literature DB >> 20978844

Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists.

Pratima Sharma1, Sameer D Saini, Latoya B Kuhn, Joel H Rubenstein, Darrell S Pardi, Jorge A Marrero, Philip S Schoenfeld.   

Abstract

BACKGROUND: Screening of high-risk patients for hepatocellular carcinoma (HCC) may result in early diagnosis and improved outcomes. Our aim was to assess gastroenterologists' knowledge of HCC management guidelines established by the American Association for the Study of Liver Diseases (AASLD) and usual clinical practice.
METHODS: We surveyed gastroenterologists attending two gastroenterology board review courses regarding their knowledge of HCC screening guidelines and usual practice of screening for HCC. Practices were compared and adherence to the 2005 published HCC guidelines was assessed.
RESULTS: The median age of gastroenterology attending physicians (n = 160) was 41 years, and 75% were men with a median of 11.5 years of practice. A total of 79% of respondents correctly identified the high-risk patients who qualify for HCC screening. Most gastroenterologists correctly identified the screening methods (88.5%) and screening interval (98%). Among those who knew guideline recommendations (i.e., correct identification and certainty of guideline recommendations), 100% reported that they followed the guideline recommendation in their own practices. Regarding the management of abnormal test, 31% of gastroenterologists did not identify that referral for liver transplantation is the recommended management strategy for small HCC in a Child B patient with cirrhosis. The number of years in clinical practice (p = 0.30) and involvement in a malpractice suit (p = 0.34) did not affect the practice patterns.
CONCLUSIONS: Most gastroenterologists correctly identified the common high-risk scenarios, methods, and interval of HCC screening as recommended by AASLD. Gastroenterologists who knew the HCC guidelines applied them in their own practice. However, approximately one-quarter do not know the appropriate management of a positive result, thereby likely hampering the overall effectiveness of screening.

Entities:  

Mesh:

Year:  2010        PMID: 20978844      PMCID: PMC3482004          DOI: 10.1007/s10620-010-1453-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

Authors:  L Bolondi; S Sofia; S Siringo; S Gaiani; A Casali; G Zironi; F Piscaglia; L Gramantieri; M Zanetti; M Sherman
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

2.  Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis.

Authors:  Rosario F Velázquez; Manuel Rodríguez; Carmen A Navascués; Antonio Linares; Ramón Pérez; Nieves G Sotorríos; Isabel Martínez; Luis Rodrigo
Journal:  Hepatology       Date:  2003-03       Impact factor: 17.425

3.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

4.  Screening for liver cancer: results of a randomised controlled trial in Qidong, China.

Authors:  J-G Chen; D M Parkin; Q-G Chen; J-H Lu; Q-J Shen; B-C Zhang; Y-R Zhu
Journal:  J Med Screen       Date:  2003       Impact factor: 2.136

5.  NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.

Authors:  Jorge A Marrero; Robert J Fontana; Grace L Su; Hari S Conjeevaram; Dawn M Emick; Anna S Lok
Journal:  Hepatology       Date:  2002-12       Impact factor: 17.425

6.  Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.

Authors:  A Singal; M L Volk; A Waljee; R Salgia; P Higgins; M A M Rogers; J A Marrero
Journal:  Aliment Pharmacol Ther       Date:  2009-04-08       Impact factor: 8.171

7.  Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection.

Authors:  Riccardo A Lencioni; Hans-Peter Allgaier; Dania Cioni; Manfred Olschewski; Peter Deibert; Laura Crocetti; Holger Frings; Joerg Laubenberger; Ina Zuber; Hubert E Blum; Carlo Bartolozzi
Journal:  Radiology       Date:  2003-05-20       Impact factor: 11.105

8.  Liver transplantation for hepatocellular carcinoma: the MELD impact.

Authors:  Pratima Sharma; Vijayan Balan; Jose L Hernandez; Ann M Harper; Erick B Edwards; Hector Rodriguez-Luna; Thomas Byrne; Hugo E Vargas; David Mulligan; Jorge Rakela; Russell H Wiesner
Journal:  Liver Transpl       Date:  2004-01       Impact factor: 5.799

9.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more
  12 in total

Review 1.  Barriers to Disease Monitoring and Liver Cancer Surveillance Among Patients with Chronic Hepatitis B in the United States.

Authors:  Simona Ispas; Samuel So; Mehlika Toy
Journal:  J Community Health       Date:  2019-06

2.  Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease.

Authors:  Kerstin Schütte; Jan Bornschein; Stefan Kahl; Ricarda Seidensticker; Jörg Arend; Jens Ricke; Peter Malfertheiner
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

Review 3.  Patient-, Provider-, and System-Level Barriers to Surveillance for Hepatocellular Carcinoma in High-Risk Patients in the USA: a Scoping Review.

Authors:  Eliza W Beal; Mackenzie Owen; Molly McNamara; Ann Scheck McAlearney; Allan Tsung
Journal:  J Gastrointest Cancer       Date:  2022-07-26

4.  Screening for hepatocellular carcinoma by Egyptian physicians.

Authors:  Sahar M Hassany; Ehab F Abdou Moustafa; Mohamed El Taher; Afaf Adel Abdeltwab; Hubert E Blum
Journal:  World J Gastrointest Oncol       Date:  2015-09-15

Review 5.  PNPLA3 genetic variation in alcoholic steatosis and liver disease progression.

Authors:  Felix Stickel; Jochen Hampe; Eric Trépo; Christian Datz; Stefano Romeo
Journal:  Hepatobiliary Surg Nutr       Date:  2015-06       Impact factor: 7.293

Review 6.  Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma.

Authors:  Renumathy Dhanasekaran; Jayant A Talwalkar
Journal:  Curr Gastroenterol Rep       Date:  2015-09

7.  Predictors of mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Pranab M Barman; Pratima Sharma; Venkat Krishnamurthy; Jonathon Willatt; Heather McCurdy; Richard H Moseley; Grace L Su
Journal:  Dig Dis Sci       Date:  2014-06-28       Impact factor: 3.199

8.  Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis.

Authors:  John F P Bridges; Liming Dong; Gisselle Gallego; Barri M Blauvelt; Susan M Joy; Timothy M Pawlik
Journal:  BMC Health Serv Res       Date:  2012-10-30       Impact factor: 2.655

9.  Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study.

Authors:  Qun Wang; Yan-Jun Zhong; Jing-Ping Yuan; Li-Hua Shao; Jue Zhang; Li Tang; Shao-Ping Liu; Ya-Ping Hong; Raymond A Firestone; Yan Li
Journal:  J Transl Med       Date:  2013-08-21       Impact factor: 5.531

10.  Caspase mediated synergistic effect of Boswellia serrata extract in combination with doxorubicin against human hepatocellular carcinoma.

Authors:  Mohammad Ahmed Khan; Mhaveer Singh; Masood Shah Khan; Abul Kalam Najmi; Sayeed Ahmad
Journal:  Biomed Res Int       Date:  2014-08-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.